Extemporaneous compounding in Queensland hospitals

Journal of Pharmacy Practice and Research

Volumn 37, Issue 3, 2007, Pages 204-207

  Cook, Graham K ^a   Ling, Joanna W H ^b   Lee, Robin ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b Morningside Central Pharmacy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMPHOTERICIN; CEFAZOLIN; ENEMA; EYE DROPS; OMEPRAZOLE; PYRAZINAMIDE; SOTALOL; VANCOMYCIN;

ARTICLE; COMPUTER ANALYSIS; CREAM; DATA ANALYSIS; DRUG FORMULATION; E-MAIL; EXPIRATION DATE; HOSPITAL PHARMACY; MICROCAPSULE; OINTMENT; PASTE; PUBLIC HOSPITAL; QUESTIONNAIRE; UNITED STATES;

EID: 35348945351     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2055-2335.2007.tb00745.x     Document Type: Article

References (30)

1. Pharmaceutical Society of Australia. Australian Pharmaceutical Formulary and Handbook. 20th ed. Canberra: Pharmaceutical Society of Australia; 2006.
2. Oceania Health Consulting. A review of the need for further regulation of extemporaneous compounding. Canberra: Therapeutic Goods Administration; 2005. Available from 〈www.tga.gov.au/meds/extempcomp.htm〉. Accessed 3 April 2007.
3. Springer V, Kisska I. Drug policy in Slovakia and its reflection in prescription. 2. Prescriptions of individually prepared drugs based on the medical specialty. Ceska Slov Farm 2002; 51: 186-9.
4. Conroy S. Extemporaneous preparation of oral medicines for children in European hospitals. Acta Paediatr 2003; 92: 408-10.
5. Standing JF, Tuleu C. Paediatric formulations - getting to the heart of the problem. Int J Pharm 2005; 300: 56-66.
6. Chui J, Tordoff J, Reith D. Changes in availability of paediatric medicines in Australia between 1998 and 2002. Br J Clin Pharmacol 2004; 59: 736-42.
7. Glass BD, Haywood A. Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products. J Pharm Pharm Sci 2006; 9: 398-426.
8. Ling MR. Extemporaneous compounding. The end of the road? Dermatol Clin 1998; 16: 321-7.
9. Nahata MC. Lack of pediatric drug formulations. Pediatrics 1999; 104: 607-9.
10. Brion F, Nunn AJ, Rieutord A. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals. Acta Paediatr 2003; 92: 486-90.
11. Rappaport PL. Extemporaneous dosage preparations for pediatrics. Can J Hosp Pharm 1983; 36: 66-70.
12. Crawford SY, Dombrowski SR. Extemporaneous compounding activities and the associated informational needs of pharmacists. Am J Hosp Pharm 1991; 48: 1205-10.
13. Crawford SY, Narducci WA, Augustine SC. National survey of quality assurance activities for pharmacy-prepared sterile products in hospitals. Am J Hosp Pharm 1991; 48: 2398-413.
14. Santell JP, Kamalich RF. National survey of quality assurance activities for pharmacy-prepared sterile products in hospitals and home infusion facilities-1995. Am J Health Syst Pharm 1996; 53: 2591-605.
15. Prankerd RJ. Extemporaneous compounding [editorial]. J Pharm Pract Res 2005; 35: 173.
16. Nahata MC. Pediatric drug formulations: challenges and potential solutions. Ann Pharmacother 1999; 33: 247-9.
17. Society of Hospital Pharmacists of Australia Working Party on Pharmaceutical Manufacturing. Report on pharmaceutical manufacturing activities in Australian hospital pharmacy departments. Aust J Hosp Pharm 1991; 21: 51-5.
18. Australian Government. National Medicines Policy. Canberra: Department of Health and Ageing 2000. Available from 〈www.health.gov.au〉. Accessed 22 November 2006.
19. Australian Institute of Health and Welfare. Australian hospital statistics 2004-2005. Canberra: AIHW; 2006. Available from 〈www.aihw.gov. au/publications〉 Accessed 16 January 2007.
20. Kairuz T, Chhim S, Hasan F, Kumar K, Lal A, Patel R, et al. Extemporaneous compounding in a sample of New Zealand hospitals: a retrospective survey. N Z Med J 2007; 120: 1-9.
21. Nahata MC, Morosco RS, Brady MT. Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children. Am J Health Syst Pharm 2006; 63: 254-7.
22. Nahata MC, Morosco RS, Willhite EA. Stability of nifedipine in two oral solutions stored at two temperatures. J Am Pharm Assoc 2002; 42: 865-7.
23. Reynolds LA, Closson RG, editors. Extemporaneous ophthalmic preparations. Vancouver: Applied Therapeutics; 1993.
24. Anaizi NH, Swenson CF, Dentinger PJ. Stability of acetylcysteine in an extemporaneously compounded ophthalmic solution. Am J Health Syst Pharm 1997; 54: 549-53.
25. Golightly LK, Smolinske SS, Bennett ML, Sutherland EW 3rd, Rumack BH. Pharmaceutical excipients. Adverse effects associated with inactive ingredients in drug products (Part 1). Med Toxicol Adverse Drug Exp 1988; 3: 128-65.
26. US Pharmacopeial Convention. US pharmacopeia and the national formulary. 19th ed. Rockville: US Pharmacopeial Convention; 1989. p. 2128.
27. Committee for Medicinal Products for Human Use. Reflection paper: formulations of choice for the paediatric population. London: European Medicines Agency; 2006. Available from 〈www.emea.europa.eu/〉. Accessed 4 April 2007.
28. Haywood A, Mangan M, Grant G, Glass B. Extemporaneous isoniazid mixture: stability implications. J Pharm Pract Res 2005; 35: 181-2.
29. National Coordinating Committee on Therapeutic Goods. Standard for the preparation of pharmaceuticals in Australian hospital pharmacy departments. Aust J Hosp Pharm 1994; 24: 182-8
30. Australian Government. Review of the need for further regulation of extemporaneous compounding. Canberra: Therapeutic Goods Administration; 2005. Available from 〈www.tga.gov.au/meds/extempcomp.htm〉. Accessed 27 June 2007.